Related Experiment Video
Updated: May 28, 2026
05:55
Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats
Published on: September 27, 2024
Update on glucocorticoid-induced osteoporosis
1Department of Medicine, University of Arizona School of Medicine, 1501 North Campbell, Tucson, AZ 85724, USA. mikemaricic@msn.com
Rheumatic Diseases Clinics of North America
|October 26, 2011
Summary
Glucocorticoid-induced osteoporosis (GIOP) is a common secondary osteoporosis. While effective treatments and guidelines exist, many patients still lack adequate prevention and therapy for this condition.
Area of Science:
- Endocrinology
- Bone Metabolism
- Pharmacology
Background:
- Glucocorticoid-induced osteoporosis (GIOP) is the most prevalent secondary osteoporosis.
- Fractures are a common adverse effect of glucocorticoid therapy.
- Glucocorticoids negatively impact bone health by reducing osteoblast and osteocyte function and lifespan.
Purpose of the Study:
- To review recent advances in understanding and managing GIOP.
- To highlight the availability of effective pharmacologic agents and published guidelines.
- To address the gap in patient prevention and treatment for GIOP.
Main Methods:
- Literature review of recent advances in GIOP pathophysiology.
- Analysis of current pharmacologic treatments for GIOP.
- Examination of published clinical guidelines for GIOP prevention and treatment.
Main Results:
- Significant progress has been made in understanding GIOP.
- Multiple effective pharmacologic agents are available for GIOP management.
- Established guidelines exist for the prevention and treatment of GIOP.
Conclusions:
- Despite advances, optimal prevention and therapy for GIOP are not universally implemented.
- Further efforts are needed to ensure patients receive appropriate care for GIOP.
- Improved patient outcomes are possible with adherence to guidelines and available treatments.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:31Osteoclasts in Bone Remodeling
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...